Stockscreener 앱 받기
7.40
8.30%
-0.67
시간 외 거래:
7.47
0.07
+0.95%
전일 마감가:
$8.07
열려 있는:
$7.63
하루 거래량:
16,077
Relative Volume:
5.13
시가총액:
$138.40M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-17.87%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$7.40
$8.20
1주일 범위
$7.40
$9.22
52주 변동 폭
$7.40
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
(617) 433-2605
주소
1100 WINTER STREET, WALTHAM
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
7.40 | 138.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
Allovir, Inc. SEC 10-K Report - TradingView
Allovir’s chief accounting officer sells $967 in stock - Investing.com India
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
Allovir director Vikas Sinha sells $1,225 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - Finansavisen
AlloVir executes reverse stock split - Investing.com
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com
AlloVir announces reverse stock split effective January 16 - Investing.com
AlloVir shareholders approve reverse stock split - Investing.com
AlloVir appoints new CEO following leadership shakeup - Investing.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - insights.citeline.com
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BioSpectrum Asia
Kalaris Therapeutics - The Pharma Letter
Kalaris to merge with AlloVir to become publicly traded company - World Pharmaceutical Frontiers
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
Class Action Filed Against AlloVir, Inc. (ALVR)March 19, 2024 Deadline to JoinContact Levi & Korsinsky - Marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Study examines connection between retinoblastoma and maternal smoking - Ophthalmology Times
Company unveils latest generation of assistive device for the legally blind - Ophthalmology Times
Ophthalmologist and former congressman John Cooksey dies at 80 - Ophthalmology Times
WVU receives $11 million COBRE grant for visual sciences research center - Ophthalmology Times
Faricimab FDA approval: Dr. Joshua Mali shares what this new therapy will mean to retina specialists - Ophthalmology Times
Bejeweled 17th century eyeglasses on block at Sotheby’s - Ophthalmology Times
AlloVir : Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021 - MarketScreener
Lexicon Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:LXRX - Benzinga
4D Molecular Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FDMT - Benzinga
Alan S. Crandall, MD, remembered for impact on ophthalmology - Ophthalmology Times
ALVRAllovir, Inc. Latest Stock News & Market Updates - Stock Titan
COVID-19: Taking precautions with patients - Ophthalmology Times
Study: Therapy reduces proptosis, diplopia in TED - Ophthalmology Times
Dr. Shravani Mikkilineni presentation - Ophthalmology Times
Dr. Eileen S. Hwang Interview - Ophthalmology Times
Bowman layer transplantation effective in advanced keratoconus - Ophthalmology Times
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):